Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 84

1.

Desvenlafaxine vs. placebo in the treatment of persistent depressive disorder.

Hellerstein DJ, Stewart JW, Chen Y, Arunagiri V, Peterson BS, McGrath PJ.

J Affect Disord. 2019 Feb 15;245:403-411. doi: 10.1016/j.jad.2018.11.065. Epub 2018 Nov 5.

PMID:
30423468
2.

A pilot, open-label, 8-week study evaluating desvenlafaxine for treatment of major depression in methadone-maintained individuals with opioid use disorder.

El Hage C, Ghabrash MF, Dubreucq S, Brissette S, Lespérance F, Lespérance P, Ouellet-Plamondon C, Bruneau J, Jutras-Aswad D.

Int Clin Psychopharmacol. 2018 Sep;33(5):268-273. doi: 10.1097/YIC.0000000000000223.

PMID:
29738425
3.

Population Pharmacokinetics of Desvenlafaxine: Pharmacokinetics in Korean Versus US Populations.

Nichols AI, Liao S, Abbas R.

Clin Pharmacol Drug Dev. 2018 May;7(4):441-450. doi: 10.1002/cpdd.419. Epub 2017 Dec 11.

PMID:
29228473
4.

Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder.

Weihs KL, Murphy W, Abbas R, Chiles D, England RD, Ramaker S, Wajsbrot DB.

J Child Adolesc Psychopharmacol. 2018 Feb;28(1):36-46. doi: 10.1089/cap.2017.0100. Epub 2017 Nov 30.

5.

Desvenlafaxine Versus Placebo in the Treatment of Children and Adolescents with Major Depressive Disorder.

Atkinson S, Lubaczewski S, Ramaker S, England RD, Wajsbrot DB, Abbas R, Findling RL.

J Child Adolesc Psychopharmacol. 2018 Feb;28(1):55-65. doi: 10.1089/cap.2017.0099. Epub 2017 Nov 29.

6.

Effect of desvenlafaxine 50 mg and 100 mg on energy and lassitude in patients with major depressive disorder: A pooled analysis.

Lam RW, Wajsbrot DB, Meier E, Pappadopulos E, Mackell JA, Boucher M.

J Psychopharmacol. 2017 Sep;31(9):1204-1214. doi: 10.1177/0269881117719261. Epub 2017 Jul 18.

PMID:
28718346
7.

Investigation of miR-1202, miR-135a, and miR-16 in Major Depressive Disorder and Antidepressant Response.

Fiori LM, Lopez JP, Richard-Devantoy S, Berlim M, Chachamovich E, Jollant F, Foster J, Rotzinger S, Kennedy SH, Turecki G.

Int J Neuropsychopharmacol. 2017 Aug 1;20(8):619-623. doi: 10.1093/ijnp/pyx034.

8.

Do social functioning and symptoms improve with continuation antidepressant treatment of persistent depressive disorder? An observational study.

Hellerstein DJ, Hunnicutt-Ferguson K, Stewart JW, McGrath PJ, Keller S, Peterson BS, Chen Y.

J Affect Disord. 2017 Mar 1;210:258-264. doi: 10.1016/j.jad.2016.12.026. Epub 2016 Dec 20.

PMID:
28064115
9.

Efficacy of Cognitive-Behavioral Therapy for Insomnia Combined With Antidepressant Pharmacotherapy in Patients With Comorbid Depression and Insomnia: A Randomized Controlled Trial.

Manber R, Buysse DJ, Edinger J, Krystal A, Luther JF, Wisniewski SR, Trockel M, Kraemer HC, Thase ME.

J Clin Psychiatry. 2016 Oct;77(10):e1316-e1323. doi: 10.4088/JCP.15m10244.

PMID:
27788313
10.

Are Patients with Childhood Onset of Insomnia and Depression More Difficult to Treat Than Are Those with Adult Onsets of These Disorders? A Report from the TRIAD Study.

Edinger JD, Manber R, Buysse DJ, Krystal AD, Thase ME, Gehrman P, Fairholme CP, Luther J, Wisniewski S.

J Clin Sleep Med. 2017 Feb 15;13(2):205-213. doi: 10.5664/jcsm.6448.

11.

Pharmacokinetics and Tolerability of Single-Ascending Doses of Desvenlafaxine Administered to Children and Adolescents with Major Depressive Disorder.

Findling RL, Groark J, Tourian KA, Ramaker SA, Chiles D, Yang L, Nichols AI.

J Child Adolesc Psychopharmacol. 2016 Dec;26(10):909-921. Epub 2016 Jul 18.

PMID:
27428303
12.

The effects of desvenlafaxine on neurocognitive and work functioning in employed outpatients with major depressive disorder.

Lam RW, Iverson GL, Evans VC, Yatham LN, Stewart K, Tam EM, Axler A, Woo C.

J Affect Disord. 2016 Oct;203:55-61. doi: 10.1016/j.jad.2016.05.074. Epub 2016 May 31.

PMID:
27280963
13.

Clinical Experience With Desvenlafaxine in Treatment of Patients With Fibromyalgia Syndrome.

Allen R, Sharma U, Barlas S.

Clin Pharmacol Drug Dev. 2017 May;6(3):224-233. doi: 10.1002/cpdd.271. Epub 2017 Feb 17.

PMID:
27139158
14.

The effect of desvenlafaxine on cognitive functioning in employed outpatients with major depressive disorder: a substudy of a randomized, double-blind, placebo-controlled trial.

Reddy S, Fayyad R, Edgar CJ, Guico-Pabia CJ, Wesnes K.

J Psychopharmacol. 2016 Jun;30(6):559-67. doi: 10.1177/0269881116631649. Epub 2016 Mar 23.

PMID:
27009044
15.

Effect of metabolic syndrome and thyroid hormone on efficacy of desvenlafaxine 50 and 100 mg/d in major depressive disorder.

McIntyre RS, Fayyad R, Mackell JA, Boucher M.

Curr Med Res Opin. 2016;32(3):587-99. doi: 10.1185/03007995.2015.1136603. Epub 2016 Jan 13.

PMID:
26709542
16.

Comparison of efficacy, safety and brain derived neurotrophic factor (BDNF) levels in patients of major depressive disorder, treated with fluoxetine and desvenlafaxine.

Ghosh R, Gupta R, Bhatia MS, Tripathi AK, Gupta LK.

Asian J Psychiatr. 2015 Dec;18:37-41. doi: 10.1016/j.ajp.2015.10.006. Epub 2015 Oct 19.

PMID:
26514447
17.

The influences of CYP2D6 genotypes and drug interactions on the pharmacokinetics of venlafaxine: exploring predictive biomarkers for treatment outcomes.

Jiang F, Kim HD, Na HS, Lee SY, Seo DW, Choi JY, Ha JH, Shin HJ, Kim YH, Chung MW.

Psychopharmacology (Berl). 2015 Jun;232(11):1899-909. doi: 10.1007/s00213-014-3825-6. Epub 2014 Dec 17.

PMID:
25510856
18.

Desvenlafaxine 50 and 100 mg/d versus placebo for the treatment of major depressive disorder: a phase 4, randomized controlled trial.

Clayton AH, Tourian KA, Focht K, Hwang E, Cheng RF, Thase ME.

J Clin Psychiatry. 2015 May;76(5):562-9. doi: 10.4088/JCP.13m08978.

PMID:
25375652
19.

SLC6A2 and SLC6A4 variants interact with venlafaxine serum concentrations to influence therapy outcome.

Proft F, Kopf J, Olmes D, Hempel S, Schmidt B, Riederer P, Deckert J, Pfuhlmann B, Reif A, Unterecker S.

Pharmacopsychiatry. 2014 Nov;47(7):245-50. doi: 10.1055/s-0034-1390412. Epub 2014 Oct 8. Erratum in: Pharmacopsychiatry. 2015 Mar;48(2):81.

PMID:
25295552
20.

Open-label, 2-period sequential drug interaction study to evaluate the effect of a 100-mg dose of desvenlafaxine on the pharmacokinetics of tamoxifen when coadministered in healthy postmenopausal female subjects.

Nichols AI, Lubaczewski S, Liang Y, Matschke K, Braley G, Ramey T.

Int J Clin Pharmacol Ther. 2014 Oct;52(10):830-41. doi: 10.5414/CP201958.

PMID:
25138680

Supplemental Content

Loading ...
Support Center